CompletedEUCTR 2006-003475-13

A SIXTEEN-WEEK, MULTI-CENTER, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF SWITCHING FROM QUETIAPINE TO ZIPRASIDONE IN SUBJECTS DIAGNOSED WITH SCHIZOPHRENIA OR SCHIZOAFFECT...

This historical record does not confirm current site availability.

Historical research recordGermany + Greece

The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Germany · Greece
Study phase: Phase 4

Study clarity

Study information

Study start dateNot clearly listed

Recruitment status: Completed
Enrollment listed in the registry: 250
Sponsor: Pfizer Pharma GmbH
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 4
Locations: Germany, Greece
Age range: Not clearly listed
Official registry ID: EUCTR 2006-003475-13
Official title: Show the full official title
A SIXTEEN-WEEK, MULTI-CENTER, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF SWITCHING FROM QUETIAPINE TO ZIPRASIDONE IN SUBJECTS DIAGNOSED WITH SCHIZOPHRENIA OR SCHIZOAFFECT...

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Germany · Greece

Registry details

Historical country statuses

Germany — Completed
Greece — Completed

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Pfizer Pharma GmbH, a pharmaceutical company.

Explore other studies

Want to find a study that may fit you better?

Explore HopeStage studies by mental health topic and refine the results to suit your situation.

Find a study that may fit me